{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:40Z","timestamp":1793330800088,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eururo.2025.09.4152","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:13:10Z","timestamp":1759875190000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Erdafitinib in Patients with High- and Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-9598","authenticated-orcid":false,"given":"Siamak","family":"Daneshmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Vasdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Galanternik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Deprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Naini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Triantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi K.","family":"Maranchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.4152_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2025.09.4152_b0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.09.4152_b0025","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/cancers16101843","article-title":"Treatment modalities for non-muscle invasive bladder cancer: an updated review","volume":"16","author":"McNall","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2025.09.4152_b0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0040","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1001\/jama.2022.7393","article-title":"Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial","volume":"327","author":"Catto","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.09.4152_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/BLC-180202","article-title":"Recovering from cystectomy: patient perspectives","volume":"5","author":"McMullen","year":"2019","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2025.09.4152_b0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2025.09.4152_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12935-020-01731-9","article-title":"Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing","volume":"21","author":"Shao","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.eururo.2025.09.4152_b0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0070","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1519428","article-title":"Updated review on novel therapies and ongoing clinical trials for high-risk non-muscle invasive bladder cancer","volume":"15","author":"Wiesen","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0090","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.eururo.2025.09.4152_b0095","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2018.36.15_suppl.4503","article-title":"First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)","volume":"36","author":"Siefker-Radtke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0100","unstructured":"BALVERSA\u00ae (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products LP; 2024."},{"key":"10.1016\/j.eururo.2025.09.4152_b0105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Alfred Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0110","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0125","unstructured":"ADSTILADRIN\u00ae (erdafitinib) [prescribing information]. Kastrup, Denmark: Ferring Pharmaceuticals; 2024."},{"key":"10.1016\/j.eururo.2025.09.4152_b0130","unstructured":"ANKTIVA [prescribing information]. Culver City, CA: ImmunityBio, Inc; 2024."},{"key":"10.1016\/j.eururo.2025.09.4152_b0135","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.4152_b0140","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.09.4152_b0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.4152_b0155","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.4152_b0165","first-page":"e987","article-title":"PD48-02 First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non\u2013muscle-invasive bladder cancer with select FGFR alterations","volume":"211","author":"Vilaseca Cabo","year":"2024","journal-title":"J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825047025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825047025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:15:21Z","timestamp":1773148521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825047025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0302283825047025"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4152","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erdafitinib in Patients with High- and Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Janssen Global Services LLC. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}